+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study



Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study



Journal of Managed Care and Specialty Pharmacy 25(5): 544-554



Statins are effective in helping prevent cardiovascular disease (CVD). However, studies suggest that only 20%-64% of patients taking statins achieve reasonable low-density lipoprotein cholesterol (LDL-C) thresholds. On-treatment levels of LDL-C remain a key predictor of residual CVD event risk. To (a) determine how many patients on statins achieved the therapeutic threshold of LDL-C < 100 mg per dL (general cohort) and < 70 mg per dL (secondary prevention cohort, or subcohort, with preexisting CVD); (b) estimate the number of potentially avoidable CVD events if the threshold were reached; and (c) forecast potential cost savings. A retrospective, longitudinal cohort study using electronic health record data from the Indiana Network for Patient Care (INPC) was conducted. The INPC provides comprehensive information about patients in Indiana across health care organizations and care settings. Patients were aged > 45 years and seen between January 1, 2012, and October 31, 2016 (ensuring study of contemporary practice), were statin-naive for 12 months before the index date of initiating statin therapy, and had an LDL-C value recorded 6-18 months after the index date. Subsequent to descriptive cohort analysis, the theoretical CVD risk reduction achievable by reaching the threshold was calculated using Framingham Risk Score and Cholesterol Treatment Trialists' Collaboration formulas. Estimated potential cost savings used published first-year costs of CVD events, adjusted for inflation and discounted to the present day. Of the 89,267 patients initiating statins, 30,083 (33.7%) did not achieve the LDL-C threshold (subcohort: 58.1%). In both groups, not achieving the threshold was associated with patients who were female, black, and those who had reduced medication adherence. Higher levels of preventive aspirin use and antihypertensive treatment were associated with threshold achievement. In both cohorts, approximately 64% of patients above the threshold were within 30 mg per dL of the respective threshold. Adherence to statin therapy regimen, judged by a medication possession ratio of ≥ 80%, was 57.4% in the general cohort and 56.7% in the subcohort. Of the patients who adhered to therapy, 23.7% of the general cohort and 50.5% of the subcohort had LDL-C levels that did not meet the threshold. 10-year CVD event risk in the at-or-above threshold group was 22.78% (SD = 17.24%) in the general cohort and 29.56% (SD = 18.19%) in the subcohort. By reducing LDL-C to the threshold, a potential relative risk reduction of 14.8% in the general cohort could avoid 1,173 CVD events over 10 years (subcohort: 15.7% and 454 events). Given first-year inpatient and follow-up costs of $37,300 per CVD event, this risk reduction could save about $1,455 per patient treated to reach the threshold (subcohort: $1,902; 2017 U.S. dollars) over a 10-year period. Across multiple health care systems in Indiana, between 34% (general cohort) and 58% (secondary prevention cohort) of patients treated with statins did not achieve therapeutic LDL-C thresholds. Based on current CVD event risk and cost projections, such patients seem to be at increased risk and may represent an important and potentially preventable burden on health care costs. Funding support for this study was provided by Merck (Kenilworth, NJ). Chase and Boggs are employed by Merck. Simpson is a consultant to Merck and Pfizer. The other authors have nothing to disclose.

(PDF emailed within 0-6 h: $19.90)

Accession: 066739537

Download citation: RISBibTeXText

PMID: 31039062

DOI: 10.18553/jmcp.2019.25.5.544


Related references

Hyperlipidemia, statin use and the risk of developing depression: a nationwide retrospective cohort study. General Hospital Psychiatry 36(5): 497-501, 2015

Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study. Cancer Management and Research 11: 1189-1197, 2019

Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis 243(1): 11-18, 2016

Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Annals of the Rheumatic Diseases 76(10): 1737-1742, 2017

Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study. Plos One 13(1): E0191129, 2018

Statin use in patients with cirrhosis: a retrospective cohort study. Digestive Diseases and Sciences 59(8): 1958-1965, 2014

Statin Use and the Risk for Incident Diabetes Mellitus in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Population-Based Retrospective Cohort Study in Taiwan. Canadian Journal of Diabetes 40(3): 264-269, 2017

Reduction of surgery rate in endometriosis patients who take Chinese medicine: a population-based retrospective cohort study. Complementary Therapies in Medicine 22(4): 632-639, 2015

Risk of fractures in vitiligo patients treated with phototherapy-A retrospective population-based cohort study. Journal of Dermatological Science 82(3): 197-203, 2017

Association between Statin Use and Sepsis Risk in Patients with Dementia: A Retrospective Cohort Study. International Journal of Environmental Research and Public Health 16(9), 2019

Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. Bmc Cardiovascular Disorders 16: 13, 2016

Risk of Delayed Healing of Tooth Extraction Wounds and Osteonecrosis of the Jaw among Patients Treated with Potential Immunosuppressive Drugs: A Retrospective Cohort Study. Tohoku Journal of Experimental Medicine 246(4): 257-264, 2018

The influence of physicians' guideline compliance on patients' statin adherence: a retrospective cohort study. American Journal of Geriatric PharmacoTherapy 3(4): 229-239, 2006

Prior statin use and the outcomes in patients with first-attack acute pancreatitis: A retrospective cohort study. European Journal of Internal Medicine 26(6): 425-428, 2016

Hyperlipidemia in COPD is associated with decreased incidence of pneumonia and mortality: a nationwide health insurance data-based retrospective cohort study. International Journal of Chronic Obstructive Pulmonary Disease 11: 1053-1059, 2017